Not in the US, but biosimilar infliximab (CT-P13) is being used subcutaneously in the EU and Canada. Analysis of 2 RCTs shows (compared to IV inflectra or remicade) SC CT-P13 greater DAS28-CRP, CDAI and SDAI response rates. https://t.co/prSVJ0BIdd